Non-Cystic Fibrosis Bronchiectasis Pipeline Insights, 2021

April 21 20:33 2021
Non-Cystic Fibrosis Bronchiectasis Pipeline Insights, 2021

Non-Cystic Fibrosis Bronchiectasis Pipeline” has been added to DelveInsight

 

Non-Cystic Fibrosis Bronchiectasis Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitors, launch date along with product development activities.

 

Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Non-Cystic Fibrosis Bronchiectasis Overview

Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.

 

Non-Cystic Fibrosis Bronchiectasis Symptoms

Symptoms include chronic (lasting more than four weeks) wet or productive cough, shortness of breath, abnormal chest sounds, weakness, weight loss and fatigue. Recurrent chest infections may produce coloured mucus. A chronic wet cough is often the only symptom present for some children with bronchiectasis.

 

Non-Cystic Fibrosis Bronchiectasis Diagnosis

Bronchiectasis is diagnosed via a chest computed tomography (CT) scan. A chest X-ray, bronchoscopy, lung function, blood tests, sputum culture, and other tests (e.g. immune function, sweat test and genetics) for associated diseases may also be performed.

 

Non-Cystic Fibrosis Bronchiectasis Treatment

  • Early use of antibiotics for acute flare-ups or epsiodes
  • Daily airway clearance techniques (chest physiotherapy – see below)
  • Appropriate vaccinations
  • Avoiding irritants such as cigarette smoke
  • Bronchodilators (only if asthma is also present)

 

Non-Cystic Fibrosis Bronchiectasis Emerging Drug

  • CHF 6333: Chiesi Farmaceutici

HF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases. CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition of Human Neutrofil Elastase.

 

Non-Cystic Fibrosis Bronchiectasis Key Players

  • Aradigm Corporation
  • Zambon
  • Novartis Pharmaceuticals
  • Insmed Incorporated

 

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Analysis

The dynamics of Non‐Cystic Fibrosis Bronchiectasis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and incremental healthcare spending across the world. Key players in the therapeutic market of Non‐Cystic Fibrosis Bronchiectasis at the global level are Zambon, Novartis, Insmed, Aradigm Corporation and others. Expected launch of these emerging therapies Colistimethate sodium (Zambon), INS1007 (Insmed), Ciprofloxacin dispersion for inhalation (Aradigm Corporation), and others will significantly impact the Non‐Cystic Fibrosis Bronchiectasis market during the forecast period (2021–2030).

 

Non-Cystic Fibrosis Bronchiectasis Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-cystic Fibrosis Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve Non-cystic Fibrosis Bronchiectasis.
  • September 2020: US biotech Insmed has trumpeted updated phase 2 data from its brensocatib, at this week’s virtual European Respiratory Society conference, showing the drug prolonged time to exacerbations caused by the rare lung disease known as non-cystic fibrosis bronchiectasis (NCFBE).

 

Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Following is the TOC of Non-cystic Fibrosis Bronchiectasis Pipeline Report

  • Introduction
  • Executive Summary
  • Non-cystic Fibrosis Bronchiectasis: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Non-cystic Fibrosis Bronchiectasis – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Non-cystic Fibrosis Bronchiectasis Collaboration Deals
  • Mid Stage Products (Phase II)
  • Brensocatib: Insmed
  • Early Stage Products (Phase I)
  • CHF-6333: Chiesi Farmaceutici
  • Pre-clinical and Discovery Stage Products
  • Inactive Products
  • Non-cystic Fibrosis Bronchiectasis Key Companies
  • Non-cystic Fibrosis Bronchiectasis Key Products
  • Non-cystic Fibrosis Bronchiectasis- Unmet Needs
  • Non-cystic Fibrosis Bronchiectasis- Market Drivers and Barriers
  • Non-cystic Fibrosis Bronchiectasis- Future Perspectives and Conclusion
  • Non-cystic Fibrosis Bronchiectasis Analyst Views
  • Non-cystic Fibrosis Bronchiectasis Key Companies
  • Appendix

 

What are the key questions answered?

  • How many companies are developing Non-cystic Fibrosis Bronchiectasis drugs?
  • How many Non-cystic Fibrosis Bronchiectasis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-cystic Fibrosis Bronchiectasis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-cystic Fibrosis Bronchiectasis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non-cystic Fibrosis Bronchiectasis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

view more articles

About Article Author